Company news
Wave Life Sciences Ltd. (NASDAQ:WVE) news
Wave Life Sciences Ltd. news releases on 6ix. Latest, Oct 1, 2026: Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA…
Press releases & updates
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
September 30, 2026
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
October 1, 2026
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
September 29, 2026
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
September 30, 2026
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
September 23, 2026
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
September 22, 2026
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
September 3, 2026
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
August 10, 2026
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
August 5, 2026
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
July 23, 2026
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
July 7, 2026
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
June 24, 2026
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
May 18, 2026
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
May 18, 2026
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
May 13, 2026
Wave Life Sciences : Amendment to Annual Report (Form 10-K/A)
April 30, 2026
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
April 27, 2026
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
April 22, 2026
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
April 21, 2026
Wave Life Sciences Announces Proposed Redomiciliation to the United States
April 14, 2026
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
March 25, 2026
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
March 4, 2026
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 23, 2026
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
February 19, 2026
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
February 2, 2026
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
January 12, 2026
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 8, 2025
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 7, 2025
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
December 7, 2025
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
December 6, 2025
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
November 9, 2025
Wave Life Sciences to Present at Upcoming Investor Conferences
November 6, 2025
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
November 3, 2025
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
November 3, 2025
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
October 28, 2025
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
October 28, 2025
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
September 24, 2025
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
September 17, 2025
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
September 2, 2025
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
July 29, 2025
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
July 22, 2025
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
June 19, 2025
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
May 28, 2025
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer
May 27, 2025
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
April 30, 2025
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
March 25, 2025